Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/715446/000149315222000302/form10-k.htm
Cover - USD ($) | 12 Months Ended | ||
|---|---|---|---|
Oct. 31, 2021 | Jan. 04, 2022 | Apr. 30, 2021 | |
| Cover [Abstract] | |||
| Document Type | 10-K | ||
| Amendment Flag | false | ||
| Document Annual Report | true | ||
| Document Transition Report | false | ||
| Document Period End Date | Oct. 31, 2021 | ||
| Document Fiscal Period Focus | FY | ||
| Document Fiscal Year Focus | 2022 | ||
| Current Fiscal Year End Date | --10-31 | ||
| Entity File Number | 001-37492 | ||
| Entity Registrant Name | ANIXABIOSCIENCES, INC. | ||
| Entity Central Index Key | 0000715446 | ||
| Entity Tax Identification Number | 11-2622630 | ||
| Entity Incorporation, State or Country Code | DE | ||
| Entity Address, Address Line One | 3150Almaden Expressway | ||
| Entity Address, Address Line Two | Suite250 | ||
| Entity Address, City or Town | SanJose | ||
| Entity Address, State or Province | CA | ||
| Entity Address, Postal Zip Code | 95118 | ||
| City Area Code | 408 | ||
| Local Phone Number | 708-9808 | ||
| Title of 12(b) Security | Common Stock, $.01 par value | ||
| Trading Symbol | ANIX | ||
| Security Exchange Name | NASDAQ | ||
| Entity Well-known Seasoned Issuer | No | ||
| Entity Voluntary Filers | No | ||
| Entity Current Reporting Status | Yes | ||
| Entity Interactive Data Current | Yes | ||
| Entity Filer Category | Non-accelerated Filer | ||
| Entity Small Business | true | ||
| Entity Emerging Growth Company | false | ||
| Entity Shell Company | false | ||
| Entity Public Float | $ 139,830,036 | ||
| Entity Common Stock, Shares Outstanding | 30,132,319 |
View differences made from one year to another to evaluate Anixa Biosciences Inc's financial trajectory
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Anixa Biosciences Inc.
ANIX Annual Reports
-
10-K Annual Report January 2022
- 10-K Annual Report January 2021
- 10-K Annual Report January 2020
- 10-K Annual Report January 2019
Rating
Learn More
Filter by Sentiment:
Filter by Category:
Filter by Subcategory:
-
Other - Other Highlight
37 The net loss attributable to noncontrolling interest, representing Wistar's 5% ownership interest in Certainty's net loss, increased by approximately $100,000 to approximately $174,000 in fiscal year 2021, from approximately $74,000 in fiscal year 2020, as Certainty's net loss increased.
-
Revenue - Product Highlight
Accordingly, the performance obligations from the license were satisfied and 100% of the revenue was recognized upon execution of the license agreement.
-
Revenue - Product Highlight
Accordingly, the performance obligations from these agreements were satisfied and 100% of the revenue was recognized upon the execution of the agreements.
-
Financial - Shares Highlight
Cash provided by financing activities was approximately $31,566,000, resulting from net proceeds of approximately $20,292,000 from a public offering of 4,285,715 shares of common stock, the sale of 2,806,410 shares of common stock in an at-the-market equity offering of approximately $10,834,000, proceeds from exercise of stock options of approximately $434,000 and proceeds from the sale of common stock pursuant to employee stock purchase plan of approximately $6,000.
-
Revenue - Product
Cash used in investing activities...Read more
-
Financial - Income
Interest income decreased to approximately...Read more
-
Financial - Cash Flow
We can give no assurance...Read more
-
Other - Other
As a result, our cash,...Read more
-
Financial - Expense
General and administrative expenses increased...Read more
-
Financial - Expense
The increase in Certainty's net...Read more
-
Revenue - Product
Our revenue arrangements provide for...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-K Annual Report
SEC Filing Financial Summary
Excel Download
Loading SEC Filing Financial Summary...
Material Contracts, Statements, Certifications & more
Anixa Biosciences Inc provided additional information to their SEC Filing as exhibits
SEC Filing Exhibit
PDF Download
Loading SEC Filing Exhibit...
Ticker: ANIX
CIK: 715446
Form Type: 10-K Annual Report
Accession Number: 0001493152-22-000302
Submitted to the SEC: Tue Jan 04 2022 4:06:16 PM EST
Accepted by the SEC: Tue Jan 04 2022
Period: Sunday, October 31, 2021
Industry: Medical Laboratories
External Resources:
Stock Quote
Social Media
Bookmark the Permalink: https://last10k.com/sec-filings/anix/0001493152-22-000302.htm
